BRIUMVI
Active substance: ublituximab
INJECTION, SOLUTION, CONCENTRATE · UBLITUXIMAB 150 mg/6mL
United StatesActive
Marketing holder: TG Therapeutics, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- UBLITUXIMAB · 150 mg/6mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1209c-1a0c-7364-b1d0-e8f1d235e8e5;count=1 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 73150-150
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
Sources
- product · openFDA NDC · 73150-150 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 73150-150 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 73150-150 · Verified 2026-10-09 · open in source